Zenas BioPharma, Inc.
ZBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Zenas BioPharma, Inc. (ZBIO) is listed under Biotechnology. The company carries a $1.86B market cap, placing it firmly in the small-cap category. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Market Cap
$1.86B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-13.04
EPS (TTM)
$-9.50
EPS (Fwd)
$-2.27
ROE
-137.1%
ROA
-29.1%
Cash
$717.2M
Total Debt
$266.8M
Free CF
-$166.3M
52W Change
115.1%
Annual Financials
Cash vs Debt
With $717.2M in cash and $266.8M in debt, ZBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$166.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -137.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ZBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.